Patents by Inventor Curtis Wright

Curtis Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150140095
    Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 21, 2015
    Inventors: Benjamin OSHLACK, Curtis WRIGHT, Derek PRATER
  • Patent number: 9034377
    Abstract: The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady state Cave and the steady state AUC of the first and second dosage forms are dose proportional and the single dose Cmax of the second dosage form is less than the minimum level for dose proportionality with respect to the first dosage form. The present invention also relates to methods of administering such dosage forms to a patient, as well as to kits comprising such dosage forms and instructions for administration of the dosage forms to a patient. The inventors believe that the dosage forms and methods of the present invention will lead to improved safety and patient acceptance.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 19, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: Curtis Wright, Robert Colucci, Ahmed El-Tahtawy
  • Patent number: 9034376
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: May 19, 2015
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20150110879
    Abstract: Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.
    Type: Application
    Filed: July 17, 2014
    Publication date: April 23, 2015
    Inventors: Christopher Breder, Curtis Wright, Benjamin Oshlack
  • Publication number: 20150105467
    Abstract: The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Applicant: JAVELIN PHARMACEUTICALS, INC.
    Inventors: Curtis Wright, Daniel B. Carr, Fred H. Mermelstein
  • Patent number: 9005659
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: April 14, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 8999961
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: April 7, 2015
    Assignees: Purdue Pharma, L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20150092190
    Abstract: Methods of obtaining a multidimensional image of a sample are provided comprising (a) directing a first coherent light pulse having a first frequency ?1 and a first wave vector k1 at a first location in the sample, (b) directing a second coherent light pulse having a second frequency ?2 and a second wave vector k2 at the first location, (c) directing a third coherent light pulse having a third frequency ?3 and a third wave vector k3 at the first location and (d) detecting a coherent output signal having a fourth frequency ?4 and a fourth wave vector k4. At least two, but optionally all three, of the coherent light pulses each excite a different transition to a discrete quantum state (e.g., transitions to vibrational states or to electronic states) of a molecule or molecular functionality in the sample. Steps (a)-(d) are repeated at a sufficient number of other locations in the sample to provide the multidimensional image.
    Type: Application
    Filed: September 29, 2014
    Publication date: April 2, 2015
    Inventors: John Curtis Wright, Erin Selene Boyle
  • Publication number: 20150080423
    Abstract: Disclosed is a pharmaceutical composition comprising from about 5 to about 20 mg of hydrocodone or a pharmaceutically acceptable salt thereof and from 0.055 to about 0.56 mg naltrexone or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 1, 2014
    Publication date: March 19, 2015
    Inventors: Benjamin OSHLACK, Curtis WRIGHT, Chris BREDER
  • Patent number: 8946292
    Abstract: The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 75 mg, e.g., from about 18.75 mg to about 37.5 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: February 3, 2015
    Assignee: Javelin Pharmaceuticals, Inc.
    Inventors: Curtis Wright, Daniel B. Carr, Fred H. Mermelstein
  • Publication number: 20150031718
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
    Type: Application
    Filed: August 27, 2014
    Publication date: January 29, 2015
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 8936812
    Abstract: Disclosed is a substantially non-releasable form of an opioid antagonist containing the opioid antagonist combined with one or more pharmaceutically acceptable hydrophobic material(s) such that the antagonist is not released or substantially not released during its transit through the gastrointestinal tract when administered orally in an intact oral dosage form. Oral dosage forms containing an opioid agonist and a substantially non-releasable form of an opioid antagonist are also disclosed.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: January 20, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J.David Haddox
  • Publication number: 20150005331
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: August 27, 2014
    Publication date: January 1, 2015
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20150005333
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: September 11, 2014
    Publication date: January 1, 2015
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20140371257
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 18, 2014
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20140357657
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 8871265
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: October 28, 2014
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20140303571
    Abstract: The present invention relates to a titratable dosage transdermal delivery system for systemic delivery of a therapeutic agent or drug. The system comprises a plurality of patch units that are connected along one or more borders. The plurality of patch units are divisible into units along the one or more borders having one or more lines of separation. Each patch unit is surrounded by a border. The therapeutic patch has at least a backing layer and a therapeutic agent comprising layer. The dosage of therapeutic agent delivered to a patient is proportional to the number of patch unit applied per treatment. The system enables systemic administration of a titratable dosage of therapeutic agent, adjustable by the patient under the direction of a physician, through the skin or mucosa. Moreover, the invention relates to a method of making the titratable dosage transdermal delivery system.
    Type: Application
    Filed: June 19, 2014
    Publication date: October 9, 2014
    Inventor: Curtis Wright IV
  • Publication number: 20140296276
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.
    Type: Application
    Filed: May 5, 2014
    Publication date: October 2, 2014
    Applicant: Purdue Pharma L.P.
    Inventors: Christopher Breder, Benjamin Oshlack, Curtis Wright
  • Patent number: 8815287
    Abstract: Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: August 26, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: Christopher Breder, Curtis Wright, Benjamin Oshlack